BRIEF

on Xlife Sciences AG (isin : CH0461929603)

Xlife Sciences AG Announces Collaboration with T-Systems Switzerland for AI-Powered Radiology Software

Xlife Sciences is excited to reveal a collaboration between its subsidiary, FUSE-AI GmbH, and T-Systems Switzerland. This partnership aims to distribute the AI-based radiology software, "Prostate.Carcinoma.ai," throughout Switzerland. T-Systems Switzerland, a key IT and digitalization entity in Swiss healthcare, will play a pivotal role in commercializing this innovative solution, designed to improve prostate analysis efficiency in radiological clinics and practices.

"Prostate.Carcinoma.ai" offers a significant improvement in radiological examination efficiency, promising to reduce analysis time by about 30%. This advancement not only boosts productivity but also proposes considerable financial advantages for healthcare providers. Moreover, FUSE-AI aspires to drastically cut the rate of misdiagnoses in MRI scans from 14% to 1%, enhancing patient care quality.

Oliver R. Baumann, CEO of Xlife Sciences, highlights the deal as a crucial step towards integrating research excellence with market-leading healthcare solutions. The software has been certified as a Class IIa medical device in the EEA, with Switzerland recognizing its CE marking, showcasing its credibility and safety. This collaboration merges the technological and industry expertise of both firms, offering substantial benefits to healthcare facilities.

Both entities view this cooperation as an initial phase in a broader endeavor to introduce AI-supported diagnostic tools for various medical conditions, aligning with Xlife Sciences' mission to narrow the gap between technology innovation and healthcare demands.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Xlife Sciences AG news